header logo image


Page 866«..1020..865866867868..880890..»

Peripheral stem cell transplantation – Wikipedia

October 2nd, 2019 2:47 am

Peripheral blood stem cell transplantation (PBSCT), also called "Peripheral stem cell support",[1] is a method of replacing blood-forming stem cells destroyed, for example, by cancer treatment. PBSCT is now a much more common procedure than its bone marrow harvest equivalent, this is in-part due to the ease and less invasive nature of the procedure.[2][3] Studies suggest that PBSCT has a better outcome in terms of the number of hematopoietic stem cell (CD34+ cells) yield.[4]

Immature hematopoietic stem cells in the circulating blood that are similar to those in the bone marrow are collected by apheresis from a potential donor (PBSC collection). The product is then administered intravenously to the patient after treatment. The administered hematopoietic stem cells then migrate to the recipient's bone marrow, a process known as stem cell homing, where the transplanted cells override the previous bone marrow. This allows the bone marrow to recover, proliferate and continue producing healthy blood cells.

The transplantation may be autologous (an individual's own blood cells saved earlier), allogeneic (blood cells donated by someone else with matching HLA), or syngeneic (blood cells donated by an identical twin). The apheresis procedure typically lasts for 46 hours, depending on the donor's total blood volume.[5]

Granulocyte colony stimulating factor (GCSF) are naturally occurring glycoproteins that stimulate white blood cell proliferation. Filgrastim is a synthetic form of GCSF produced in E.coli.[6] PBSC donors are given a course of GCSF prior to PBSC collection, this ensures a better outcome, as stem cell proliferation increases, thus increasing the number of peripheral stem cells in circulation.The course is usually given over a 4-day period prior to PBSC collection.[7] Mild bone pain usually results due to the excessive stem cell crowding within the bone marrow.

Since allogeneic PBSCT involves transformation of blood between different individuals, this naturally carries more complications than autologous PBSCT.[8]For example, calculations must be made to ensure consistency in the amount of total blood volume between the donor and recipient. If the total blood volume of the donor is less than that of the recipient (such as when a child is donating to an adult), multiple PBSCT sessions may be required for adequate collection. Performing such a collection in a single setting could result in risks such as hypovolemia, which could lead to cardiac arrest, thus health care providers must exercise careful precaution when considering donor-recipient matching in allogeneic PBSCT[9]

An early example of a successful peripheral stem cell transplant was carried out in the wake of the 1999 Tokaimura nuclear accident. One of the two technicians who received the highest dose of radiation was treated with PBSCT in an attempt to restore his destroyed immune system. Cells from the patient's sister's bone marrow were administered, and in the following weeks successfully began dividing and differentiating into leukocytes, but several weeks later, the cells were found to have been mutated by the radiation still present within the patient's body, and were observed carrying out autoimmune responses.[10] Later studies on the incident and subsequent use of PBSCT found that the transplant had also induced neoendothelialization of the aortic endothelium.[11]

This article incorporatespublic domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".

Originally posted here:
Peripheral stem cell transplantation - Wikipedia

Read More...

Genetics of Kidney Cancer (Renal Cell Cancer) (PDQ …

October 2nd, 2019 2:47 am

More than 55% of VHL-affected individuals develop only multiple renal cell cysts. The VHL-associated RCCs that occur are characteristically multifocal and bilateral and present as a combined cystic and solid mass.[66] Among individuals with VHL, the cumulative RCC risk has been reported as 24% to 45% overall. RCCs smaller than 3 cm in this disease tend to be low grade (Fuhrman nuclear grade 2) and minimally invasive,[67] and their rate of growth varies widely.[68] An investigation of 228 renal lesions in 28 patients who were followed up for at least 1 year showed that transition from a simple cyst to a solid lesion was infrequent.[66] Complex cystic and solid lesions contained neoplastic tissue that uniformly enlarged. These data may be used to help predict the progression of renal lesions in VHL. Figure 1 depicts bilateral renal tumors in a patient with VHL.

EnlargeFigure 1. von Hippel-Lindau diseaseassociated renal cell cancers are characteristically multifocal and bilateral and present as a combined cystic and solid mass. Red arrow indicates a lesion with a solid and cystic component, and white arrow indicates a predominantly solid lesion.

Tumors larger than 3 cm may increase in grade as they grow, and metastasis may occur.[68,69] RCCs often remain asymptomatic for long intervals.

Patients can also develop pancreatic cysts, cystadenomas, and pancreatic NETs.[2] Pancreatic cysts and cystadenomas are not malignant, but pancreatic NETs possess malignant characteristics and are typically resected if they are 3 cm or larger (2 cm if located in the head of the pancreas).[70] A review of the natural history of pancreatic NETs shows that these tumors may demonstrate nonlinear growth characteristics.[71]

Retinal manifestations, first reported more than a century ago, were one of the first recognized aspects of VHL. Retinal hemangioblastomas (also known as capillary retinal angiomas) are one of the most frequent manifestations of VHL and are present in more than 50% of patients.[72] Retinal involvement is one of the earliest manifestations of VHL, with a mean age at onset of 25 years.[1,2] These tumors are the first manifestation of VHL in nearly 80% of affected individuals and may occur in children as young as 1 year.[2,73,74]

Retinal hemangioblastomas occur most frequently in the periphery of the retina but can occur in other locations such as the optic nerve, a location much more difficult to treat. Retinal hemangioblastomas appear as a bright orange spherical tumor supplied by a tortuous vascular supply. Nearly 50% of patients have bilateral retinal hemangioblastomas.[72] The median number of lesions per affected eye is approximately six.[75] Other retinal lesions in VHL can include retinal vascular hamartomas, flat vascular tumors located in the superficial aspect of the retina.[76]

Longitudinal studies are important for the understanding of the natural history of these tumors. Left untreated, retinal hemangioblastomas can be a major source of morbidity in VHL, with approximately 8% of patients [72] having blindness caused by various mechanisms, including secondary maculopathy, contributing to retinal detachment, or possibly directly causing retinal neurodegeneration.[77] Patients with symptomatic lesions generally have larger and more numerous retinal hemangioblastomas. Long-term follow-up studies demonstrate that most lesions grow slowly and that new lesions do not develop frequently.[75,78]

Hemangioblastomas are the most common disease manifestation in patients with VHL, affecting more than 70% of individuals. A prospective study assessed the natural history of hemangioblastomas.[79] The mean age at onset of CNS hemangioblastomas is 29.1 years (range, 773 y).[80] After a mean follow-up of 7 years, 72% of the 225 patients studied developed new lesions.[81] Fifty-one percent of existing hemangioblastomas remained stable. The remaining lesions exhibited heterogeneous growth rates, with cerebellar and brainstem lesions growing faster than those in the spinal cord or cauda equina. Approximately 12% of hemangioblastomas developed either peritumoral or intratumoral cysts, and 6.4% were symptomatic and required treatment. Increased tumor burden or total tumor number detected was associated with male sex, longer follow-up, and genotype (all P < .01). Partial germline deletions were associated with more tumors per patient than were missense variants (P < .01). Younger patients developed more tumors per year. Hemangioblastoma growth rate was higher in men than in women (P < .01). Figures 2 and 3 depict cerebellar and spinal hemangioblastomas, respectively, in patients with VHL.

EnlargeFigure 2. Hemangioblastomas are the most common disease manifestation in patients with von Hippel-Lindau disease. The left panel shows a sagittal view of brainstem and cerebellar lesions. The middle panel shows an axial view of a brainstem lesion. The right panel shows a cerebellar lesion (red arrow) with a dominant cystic component (white arrow).

EnlargeFigure 3. Hemangioblastomas are the most common disease manifestation in patients with von Hippel-Lindau disease. Multiple spinal cord hemangioblastomas are shown.

The rate of pheochromocytoma formation in the VHL patient population is 25% to 30%.[82,83] Of patients with VHL-associated pheochromocytomas, 44% developed disease in both adrenal glands.[84] The rate of malignant transformation is very low. Levels of plasma and urine normetanephrine are typically elevated in patients with VHL,[85] and approximately two-thirds will experience physical manifestations such as hypertension, tachycardia, and palpitations.[82] Patients with a partial loss of VHL function (Type 2 disease) are at higher risk of pheochromocytoma than are VHL patients with a complete loss of VHL function (Type 1 disease); the latter develop pheochromocytoma very rarely.[13,14,82,86] The rate of VHL germline pathogenic variants in nonsyndromic pheochromocytomas and paragangliomas was very low in a cohort of 182 patients, with only 1 of 182 patients ultimately diagnosed with VHL.[87]

Paragangliomas are rare in VHL patients but can occur in the head and neck or abdomen.[88] A review of VHL patients who developed pheochromocytomas and/or paragangliomas revealed that 90% of patients manifested pheochromocytomas and 19% presented with a paraganglioma.[84]

The mean age at diagnosis of VHL-related pheochromocytomas and paragangliomas is approximately 30 years,[83,89] and patients with multiple tumors were diagnosed more than a decade earlier than patients with solitary lesions in one series (19 vs. 34 y; P < .001).[89] Diagnosis of pheochromocytoma was made in patients as young as 5 years in one cohort,[83] providing a rationale for early testing. All 21 pediatric patients with pheochromocytomas in this 273-patient cohort had elevated plasma normetanephrines.[83]

VHL patients may develop multiple serous cystadenomas, pancreatic NETs, and simple pancreatic cysts.[1] VHL patients do not have an increased risk of pancreatic adenocarcinoma. Serous cystadenomas are benign tumors and warrant no intervention. Simple pancreatic cysts can be numerous and rarely cause symptomatic biliary duct obstruction. Endocrine function is nearly always maintained; occasionally, however, patients with extensive cystic disease requiring pancreatic surgery may ultimately require pancreatic exocrine supplementation.

Pancreatic NETs are usually nonfunctional but can metastasize (to lymph nodes and the liver). The risk of pancreatic NET metastasis was analyzed in a large cohort of patients, in which the mean age at diagnosis of a pancreatic NET was 38 years (range, 1668 y).[90] The risk of metastasis was lower in patients with small primary lesions (3 cm), in patients without an exon 3 pathogenic variant, and in patients whose tumor had a slow doubling time (>500 days). Nonfunctional pancreatic NETs can be followed by imaging surveillance with intervention when tumors reach 3 cm. Lesions in the head of the pancreas can be considered for surgery at a smaller size to limit operative complexity.

ELSTs are adenomatous tumors arising from the endolymphatic duct or sac within the posterior part of the petrous bone.[91] ELSTs are rare in the sporadic setting, but are apparent on imaging in 11% to 16% of patients with VHL. Although these tumors do not metastasize, they are locally invasive, eroding through the petrous bone and the inner ear structures.[91,92] Approximately 30% of VHL patients with ELSTs have bilateral lesions.[91,93]

ELSTs are an important cause of morbidity in VHL patients. ELSTs evident on imaging are associated with a variety of symptoms, including hearing loss (95% of patients), tinnitus (92%), vestibular symptoms (such as vertigo or disequilibrium) (62%), aural fullness (29%), and facial paresis (8%).[91,92] In approximately half of patients, symptoms (particularly hearing loss) can occur suddenly, probably as a result of acute intralabyrinthine hemorrhage.[92] Hearing loss or vestibular dysfunction in VHL patients can also present in the absence of radiologically evident ELSTs (approximately 60% of all symptomatic patients) and is believed to be a consequence of microscopic ELSTs.[91]

Hearing loss related to ELSTs is typically irreversible; serial imaging to enable early detection of ELSTs in asymptomatic patients and resection of radiologically evident lesions are important components in the management of VHL patients.[94,95] Surgical resection by retrolabyrinthine posterior petrosectomy is usually curative and can prevent onset or worsening of hearing loss and improve vestibular symptoms.[92,94]

Tumors of the broad ligament can occur in females with VHL and are known as papillary cystadenomas. These tumors are extremely rare, and fewer than 20 have been reported in the literature.[96] Papillary cystadenomas are histologically identical to epididymal cystadenomas commonly observed in males with VHL.[97] One important difference is that papillary cystadenomas are almost exclusively observed in patients with VHL, whereas epididymal cystadenomas in men can occur sporadically.[98] These tumors are frequently cystic, and although they become large, they generally have a fairly indolent behavior.

Fluid-filled epididymal cysts, or spermatoceles, are very common in adult men. In VHL, the epididymis can contain more complex cystic neoplasms known as papillary cystadenomas, which are rare in the general population. More than one-third of all cases of epididymal cystadenomas reported in the literature and most cases of bilateral cystadenomas have been reported in patients with VHL.[99] These well-circumscribed lesions have variable amounts of cystic and papillary components that are lined with epithelial cuboidal or columnar clear cells.[100] Among symptomatic patients, the most common presentation of epididymal cystadenoma is a painless, slow-growing scrotal swelling. The differential diagnoses of epididymal tumors include adenomatoid tumor (which is the most common tumor in this site), metastatic ccRCC, and papillary mesothelioma.[101]

In a small series, histological analysis did not reveal features typically associated with malignancy, such as mitotic figures, nuclear pleomorphism, and necrosis. Lesions were strongly positive for CK7 and negative for RCC. Carbonic anhydrase IX (CAIX) was positive in all tumors. PAX8 was positive in most cases. These features were reminiscent of clear cell papillary RCC, a relatively benign form of RCC without known metastatic potential.[97]

See the article here:
Genetics of Kidney Cancer (Renal Cell Cancer) (PDQ ...

Read More...

Stem Cell Therapy|PRP Injections – Regenerative Medicine

October 2nd, 2019 2:47 am

At Regenerative Medical Institute we strive to provide the safest and most effective care for our patients. Our Regenerative Medicine Program was developed to give our patients access to the most advanced treatment options with proven results. In recent years scientists and doctors have made tremendous advances in moving regenerative medicine into the mainstream as a treatment for many diseases and disorders. The reparative procedures offered at Regenerative Medical Institute, PLLC will repair damaged tissues and get you back to your active lifestyle without the need for surgery.

If youre suffering from ongoing, nagging chronic pain that hasnt benefited from other treatments,you could benefit from an exciting new area of pain management known as regenerative medicine.

These minimally-invasive treatments offer patients pain relief, while reducing the likelihood of infectionand avoiding the need for surgery. For many patients, regenerative medicines can help them get their livesback by jump-starting their bodys own natural healing processes.

Regenerative medicine includes treatments like PRP therapy and stem cell therapy.The most common conditions that have been successfully treated using regenerative medical procedures includearthritis and injuries to cartilage, tendons, muscle, bone, spinal discs, and other tissue types. For many patients,it can help them:

Chronic pain can affect a persons ability to function during daily activities and their job responsibilities. Pain increases a persons rate of physician appointments, disability claims, and loss of productivity. Using estimates from both acute and chronic pain conditions, back pain alone accounts for pain in approximately 100 million adults in the U.S.

For these patients, regenerative medicine (Stem Cells and/or PRP) may be able to help. Regenerative medicines are cutting-edge therapies that use chemistry, medicine, robotics, biology, computer science, genetics, and engineering to construct a biologically compatible structure for many different tissues found in the body. Although relatively new in the field of acute and chronic pain management, regenerative medical procedures do date back as early as 1962.

To learn More About The Regenerative Medicine Treatments Available Please Click the Links Below:

Platelet-Rich Plasma (PRP)

Stem Cell Therapy-Refill and Revive

Stem Cell Therapy Info

Stem Cell Injections

NyDyn Stem Cell Brochures for Patients

FDA Guidelines for PRP Usage

Guidelines for PRP in Sports Medicine

Statements made on this website have not been evaluated by the Food and Drug Administration. The information contained herein is not intended to diagnose, treat, cure or prevent any disease.

Read the rest here:
Stem Cell Therapy|PRP Injections - Regenerative Medicine

Read More...

College of Veterinary Medicine | Washington State University

October 2nd, 2019 2:46 am

Where have all the frogs gone? It happened again that morning. During their rounds, zookeepers found another tank of dead blue poison dart frogs.Read More

A Neuroscientists Quest to Prevent Hearing Loss Nearly 30 million people in the United States have some type of hearing loss, mostly due to aging.Read More

Working together so Kenyans can help Kenyans When Paul Allen visited East Africa, he saw how peoples daily lives could be improved and the desire for local institutions to better serve people in need.Read More

Impact Report 2017-18 119: The age of the college. The WSU College of Veterinary Medicine was established in 1899. It is the 5th oldest veterinary college in the United States.Read More

A painted horse helps students learn anatomy A life-sized painted fiberglass horse will now help WSU undergraduate and veterinary students learn anatomy thanks to a generous donor.Read More

Teaching science students visual literacy life skills Students who study molecular biosciences cant actually see what they are learning.Read More

Read more from the original source:
College of Veterinary Medicine | Washington State University

Read More...

10 Reasons to Oppose Genetic Engineering – NW RAGE

October 2nd, 2019 2:46 am

10 Reasons to Oppose Genetic Engineering

2. Health risksGenetic engineering can make foods that were once safe to eat a threat to people with allergies. Because this process is unpredictable, new substances can develop in engineered foods. The FDA knows this and does some testing, but there are no guarantees.

Besides the new allergies, inserting genes into plants and animals can cause existing genes to react in unknown ways, including reduced nutritional values and changes in organism quality.

4. Biodiversity in dangerEngineering specific traits into select species threatens the planets biodiversity by upsetting the natural balance. Engineered organisms spread uncontained into the wild. They also spread their genes into the gene pool. Once engineered organisms are released, there will be no recalls, and as they continue to upset nature, it may be impossible to undo the damage.

5. Genetic engineering is about corporate control of agricultureThe reason to engineer and patent a seed is to make money off of a captive market. Although some family farmers in the US are using this technology, they are not the driving force behind its creation. Genetically engineered crops further lock farmers into a cycle of dependence on quick fix techno schemes with royalty fees and debts to the bank.

6. Organic Agriculture is at RiskGenetically engineered plants do not recognize buffer zones and containment fields. They will drift and they will be carried wherever fate will have it. Contamination of conventional and organic crops isn't a matter of if, its a matter of when. These new creations have proven impossible to contain outside of a lab.

So who will be liable when this contamination occurs? Not the Biotech companies. Currently there are few if any laws assigning liability to life's new architects. The laws that do exist are concerned with intellectual property rights. It seems the court want to be certain you pay for every GE seed that grows, whether you planted it or not.

8. Increase in insecticide and herbicide useWhen plants are engineered to resist insecticides, farmers spray more insecticide on the plants. Couple that with pests building up insecticide resistance because of the larger usage and you have a company selling more chemicals, an environment more polluted, and a farmer more dependent.

9. Monopolization of food productionThe spread of genetic engineering coincides with widening legal possibilities to patent plants and their genes. Patents on food bear the intrinsic danger that a few transnational corporations obtain exclusive control over the whole chain of food production, from the gene to the dish. Initial conflicts over patent rights in Northern America show how, in the future, farmers may lose some of the rights concerning their crops. Patents on life are not compatible with the concept of intellectual property rights. They confer rights which go far beyond what the "inventor" has really accomplished.

Source: Basic outline and text adapted and borrowed from The Church's Statement on Genetic Engineering 2003.

Original post:
10 Reasons to Oppose Genetic Engineering - NW RAGE

Read More...

Regulation of genetic engineering – Wikipedia

October 2nd, 2019 2:46 am

The regulation of genetic engineering varies widely by country. Countries such as the United States, Canada, Lebanon and Egypt use substantial equivalence as the starting point when assessing safety, while many countries such as those in the European Union, Brazil and China authorize GMO cultivation on a case-by-case basis. Many countries allow the import of GM food with authorization, but either do not allow its cultivation (Russia, Norway, Israel) or have provisions for cultivation, but no GM products are yet produced (Japan, South Korea). Most countries that do not allow for GMO cultivation do permit research.[1]One of the key issues concerning regulators is whether GM products should be labeled. Labeling of GMO products in the marketplace is required in 64 countries.[2] Labeling can be mandatory up to a threshold GM content level (which varies between countries) or voluntary. A study investigating voluntary labeling in South Africa found that 31% of products labeled as GMO-free had a GM content above 1.0%.[3] In Canada and the USA labeling of GM food is voluntary,[4] while in Europe all food (including processed food) or feed which contains greater than 0.9% of approved GMOs must be labelled.[5]

There is a scientific consensus[6][7][8][9] that currently available food derived from GM crops poses no greater risk to human health than conventional food,[10][11][12][13][14] but that each GM food needs to be tested on a case-by-case basis before introduction.[15][16][17] Nonetheless, members of the public are much less likely than scientists to perceive GM foods as safe.[18][19][20][21] The legal and regulatory status of GM foods varies by country, with some nations banning or restricting them, and others permitting them with widely differing degrees of regulation.[22][23][24][25]

There is no evidence to support the idea that the consumption of approved GM food has a detrimental effect on human health.[26][27][28] Some scientists and advocacy groups, such as Greenpeace and World Wildlife Fund, have however called for additional and more rigorous testing for GM food.[27]

The development of a regulatory framework concerning genetic engineering began in 1975, at Asilomar, California. The first use of Recombinant DNA (rDNA) technology had just been successfully accomplished by Stanley Cohen and Herbert Boyer two years previously and the scientific community recognized that as well as benefits this technology could also pose some risks.[29] The Asilomar meeting recommended a set of guidelines regarding the cautious use of recombinant technology and any products resulting from that technology.[30] The Asilomar recommendations were voluntary, but in 1976 the US National Institute of Health (NIH) formed a rDNA advisory committee.[31] This was followed by other regulatory offices (the United States Department of Agriculture (USDA), Environmental Protection Agency (EPA) and Food and Drug Administration (FDA)), effectively making all rDNA research tightly regulated in the USA.[32]

In 1982 the Organisation for Economic Co-operation and Development (OECD) released a report into the potential hazards of releasing genetically modified organisms (GMOs) into the environment as the first transgenic plants were being developed.[33] As the technology improved and genetically organisms moved from model organisms to potential commercial products the USA established a committee at the Office of Science and Technology (OSTP) to develop mechanisms to regulate the developing technology.[32] In 1986 the OSTP assigned regulatory approval of genetically modified plants in the US to the USDA, FDA and EPA.[34]

The basic concepts for the safety assessment of foods derived from GMOs have been developed in close collaboration under the auspices of the OECD, the World Health Organization (WHO) and Food and Agriculture Organization (FAO). A first joint FAO/WHO consultation in 1990 resulted in the publication of the report Strategies for Assessing the Safety of Foods Produced by Biotechnology in 1991.[35] Building on that, an international consensus was reached by the OECDs Group of National Experts on Safety in Biotechnology, for assessing biotechnology in general, including field testing GM crops.[36] That Group met again in Bergen, Norway in 1992 and reached consensus on principles for evaluating the safety of GM food; its report, The safety evaluation of foods derived by modern technology concepts and principles was published in 1993.[37] That report recommends conducting the safety assessment of a GM food on a case-by-case basis through comparison to an existing food with a long history of safe use. This basic concept has been refined in subsequent workshops and consultations organized by the OECD, WHO, and FAO, and the OECD in particular has taken the lead in acquiring data and developing standards for conventional foods to be used in assessing substantial equivalence.[38][39]

The Cartagena Protocol on Biosafety was adopted on 29 January 2000 and entered into force on 11 September 2003.[40] It is an international treaty that governs the transfer, handling, and use of genetically modified (GM) organisms. It is focused on movement of GMOs between countries and has been called a de facto trade agreement.[41] One hundred and fifty-seven countries are members of the Protocol and many use it as a reference point for their own regulations.[42] Also in 2003 the Codex Alimentarius Commission of the FAO/WHO adopted a set of "Principles and Guidelines on foods derived from biotechnology" to help countries coordinate and standardize regulation of GM food to help ensure public safety and facilitate international trade.[43] and updated its guidelines for import and export of food in 2004,[44]

The European Union first introduced laws requiring GMO's to be labelled in 1997.[45] In 2013, Connecticut became the first state to enact a labeling law in the USA, although it would not take effect until other states followed suit.[46]

Institutions that conduct certain types of scientific research must obtain permission from government authorities and ethical committees before they conduct any experiments. Universities and research institutes generally have a special committee that is responsible for approving any experiments that involve genetic engineering. Many experiments also need permission from a national regulatory group or legislation. All staff must be trained in the use of GMOs and in some laboratories a biological control safety officer is appointed. All laboratories must gain approval from their regulatory agency to work with GMOs and all experiments must be documented.[47] As of 2008 there have been no major accidents with GMOs in the lab.[48]

The legislation covering GMOS was initially covered by adapting existing regulations in place for chemicals or other purposes, with many countries later developing specific policies aimed at genetic engineering.[49] These are often derived from regulations and guidelines in place for the non-GMO version of the organism, although they are more severe. In many countries now the regulations are diverging, even though many of the risks and procedures are similar. Sometimes even different agencies are responsible, notably in the Netherlands where the Ministry of the Environment covers GMOs and the Ministry of Social Affairs covers the human pathogens they are derived from.[48]

There is a near universal system for assessing the relative risks associated with GMOs and other agents to laboratory staff and the community. They are then assigned to one of four risk categories based on their virulence, the severity of disease, the mode of transmission, and the availability of preventive measures or treatments. There are some differences in how these categories are defined, such as the World Health Organisation (WHO) including dangers to animals and the environment in their assessments. When there are varying levels of virulence the regulators base their classification on the highest. Accordingly there are four biosafety levels that a laboratory can fall into, ranging from level 1 (which is suitable for working with agents not associated with disease) to level 4 (working with life threatening agents). Different countries use different nomenclature to describe the levels and can have different requirements for what can be done at each level.[48]

In Europe the use of living GMOs are regulated by the European Directive on the contained use of genetically modified microorganisms (GMMs).[47] The regulations require risk assessments before use of any contained GMOs is started and assurances that the correct controls are in place. It provides the minimal standards for using GMMs, with individual countries allowed to enforce stronger controls.[50] In the UK the Genetically Modified Organisms (Contained Use) Regulations 2014 provides the framework researchers must follow when using GMOs. Other legislation may be applicable depending on what research is carried out. For workplace safety these include the Health and Safety at Work Act 1974, the Management of Health and Safety at Work Regulations 1999, the Carriage of Dangerous Goods legislation and the Control of Substances Hazardous to Health Regulations 2002. Environmental risks are covered by Section 108(1) of the Environmental Protection Act 1990 and The Genetically Modified Organisms (Risk assessment) (Records and Exemptions) Regulations 1996.[51]

In the USA the National Institute of Health (NIH) classifies GMOs into four risk groups. Risk group one is not associated with any diseases, risk group 2 is associated with diseases that are not serious, risk group 3 is associated with serious diseases where treatments are available and risk group 4 is for serious diseases with no known treatments.[47] In 1992 the Occupational Safety and Health Administration determined that its current legislation already adequately covers the safety of laboratory workers using GMOs.[49]

Australia has an exempt dealing for genetically modified organisms that only pose a low risk. These include systems using standard laboratory strains as the hosts, recombinant DNA that does not code for a vertebrate toxin or is not derived from a micro-organism that can cause disease in humans. Exempt dealings usually do not require approval from the national regulator. GMOs that pose a low risk if certain management practices are complied with are classified as notifiable low risk dealings. The final classification is for any uses of GMOs that do not meet the previous criteria. These are known as licensed dealings and include cloning any genes that code for vertebrate toxins or using hosts that are capable of causing disease in humans. Licensed dealings require the approval of the national regulator.[52]

Work with exempt GMOs do not need to be carried out in certified laboratories. All others must be contained in a Physical Containment level 1 (PC1) or Physical Containment level 2 (PC2) laboratories. Laboratory work with GMOs classified as low risk, which include knockout mice, are carried out in PC1 lab. This is the case for modifications that do not confer an advantage to the animal or doesn't secrete any infectious agents. If a laboratory strain that is used isn't covered by exempt dealings or the inserted DNA could code for a pathogenic gene, it must be carried out in a PC2 laboratory.[52]

The approaches taken by governments to assess and manage the risks associated with the use of genetic engineering technology and the development and release of GMOs vary from country to country, with some of the most marked differences occurring between the United States and Europe. The United States takes on a less hands-on approach to the regulation of GMOs than in Europe, with the FDA and USDA only looking over pesticide and plant health facets of GMOs.[53] Despite the overall global increase in the production in GMOs, the European Union has still stalled GMOs fully integrating into its food supply.[54] This has definitely affected various countries, including the United States, when trading with the EU.[54][55]

European Union enacted regulatory laws in 2003 that provided possibly the most stringent GMO regulations in the world.[5] All GMOs, along with irradiated food, are considered "new food" and subject to extensive, case-by-case, science-based food evaluation by the European Food Safety Authority (EFSA). The criteria for authorization fall in four broad categories: "safety," "freedom of choice," "labelling," and "traceability."[56]

The European Parliament's Committee on the Environmental, Public Health, and Consumer Protection pushed forward and adopted a "safety first" principle regarding the case of GMOs, calling for any negative health consequences from GMOs to be held liable.

However, although the European Union has had relatively strict regulations regarding the genetically modified food, Europe is now allowing newer versions of modified maize and other agricultural produce. Also, the level of GMO acceptance in the European Union varies across its countries with Spain and Portugal being more permissive of GMOs than France and the Nordic population.[57] One notable exception however is Sweden. In this country, the government has declared that the GMO definition (according to Directive 2001/18/EC[58]) stipulates that foreign DNA needs to be present in an organism for it to qualify as a genetically modified organisms. Organisms that thus have the foreign DNA removed (for example via selective breeding[59]) do not qualify as GMO's, even if gene editing has thus been used to make the organism.[60]

In Europe the EFSA reports to the European Commission who then draft a proposal for granting or refusing the authorisation. This proposal is submitted to the Section on GM Food and Feed of the Standing Committee on the Food Chain and Animal Health and if accepted it will be adopted by the EC or passed on to the Council of Agricultural Ministers. Once in the Council it has three months to reach a qualified majority for or against the proposal, if no majority is reached the proposal is passed back to the EC who will then adopt the proposal.[5] However, even after authorization, individual EU member states can ban individual varieties under a 'safeguard clause' if there are "justifiable reasons" that the variety may cause harm to humans or the environment. The member state must then supply sufficient evidence that this is the case.[61] The Commission is obliged to investigate these cases and either overturn the original registrations or request the country to withdraw its temporary restriction.

The U.S. regulatory policy is governed by the Coordinated Framework for Regulation of Biotechnology[62] The policy has three tenets: "(1) U.S. policy would focus on the product of genetic modification (GM) techniques, not the process itself, (2) only regulation grounded in verifiable scientific risks would be tolerated, and (3) GM products are on a continuum with existing products and, therefore, existing statutes are sufficient to review the products."[63]

For a genetically modified organism to be approved for release in the U.S., it must be assessed under the Plant Protection Act by the Animal and Plant Health Inspection Service (APHIS) agency within the USDA and may also be assessed by the FDA and the EPA, depending on the intended use of the organism. The USDA evaluate the plants potential to become weeds, the FDA reviews plants that could enter or alter the food supply,[64] and the EPA regulates genetically modified plants with pesticide properties, as well as agrochemical residues.[65]

The level of regulation in other countries lies in between Europe and the United States.

Common Market for Eastern and Southern Africa (COMASA) is responsible for assessing the safety of GMOs in most of Africa, although the final decision lies with each individual country.[66]

India and China are the two largest producers of genetically modified products in Asia.[67] The Office of Agricultural Genetic Engineering Biosafety Administration (OAGEBA) is responsible for regulation in China,[68] while in India it is the Institutional Biosafety Committee (IBSC), Review Committee on Genetic Manipulation (RCGM) and Genetic Engineering Approval Committee (GEAC).[69]

Brazil and Argentina are the 2nd and 3rd largest producers of GM food.[70] In Argentine assessment of GM products for release is provided by the National Agricultural Biotechnology Advisory Committee (environmental impact), the National Service of Health and Agrifood Quality (food safety) and the National Agribusiness Direction (effect on trade), with the final decision made by the Secretariat of Agriculture, Livestock, Fishery and Food.[71] In Brazil the National Biosafety Technical Commission is responsible for assessing environmental and food safety and prepares guidelines for transport, importation and field experiments involving GM products, while the Council of Ministers evaluates the commercial and economical issues with release.[71]

Health Canada and the Canadian Food Inspection Agency[72] are responsible for evaluating the safety and nutritional value of genetically modified foods released in Canada.[73]

License applications for the release of all genetically modified organisms in Australia is overseen by the Office of the Gene Technology Regulator, while regulation is provided by the Therapeutic Goods Administration for GM medicines or Food Standards Australia New Zealand for GM food. The individual state governments can then assess the impact of release on markets and trade and apply further legislation to control approved genetically modified products.[74][75]

One of the key issues concerning regulators is whether GM products should be labeled. Labeling can be mandatory up to a threshold GM content level (which varies between countries) or voluntary. A study investigating voluntary labeling in South Africa found that 31% of products labeled as GMO-free had a GM content above 1.0%.[3] In Canada and the United States labeling of GM food is voluntary,[4] while in Europe all food (including processed food) or feed which contains greater than 0.9% of approved GMOs must be labelled.[5] In the US state of Oregon., voters rejected Measure 27, which would have required labeling of all genetically modified foods.[80] Japan, Malaysia, New Zealand, and Australia require labeling so consumers can exercise choice between foods that have genetically modified, conventional or organic origins.[81]

The Cartagena Protocol sets the requirements for the international trade of GMO's between countries that are signatories to it. Any shipments contain genetically modified organisms that are intended to be used as feed, food or for processing must be identified and a list of the transgenic events be available.

"Substantial equivalence" is a starting point for the safety assessment for GM foods that is widely used by national and international agenciesincluding the Canadian Food Inspection Agency, Japan's Ministry of Health and Welfare and the U.S. Food and Drug Administration, the United Nations Food and Agriculture Organization, the World Health Organization and the OECD.[82]

A quote from FAO, one of the agencies that developed the concept, is useful for defining it: "Substantial equivalence embodies the concept that if a new food or food component is found to be substantially equivalent to an existing food or food component, it can be treated in the same manner with respect to safety (i.e., the food or food component can be concluded to be as safe as the conventional food or food component)".[83] The concept of substantial equivalence also recognises the fact that existing foods often contain toxic components (usually called antinutrients) and are still able to be consumed safelyin practice there is some tolerable chemical risk taken with all foods, so a comparative method for assessing safety needs to be adopted. For instance, potatoes and tomatoes can contain toxic levels of respectively, solanine and alpha-tomatine alkaloids.[84][85]

To decide if a modified product is substantially equivalent, the product is tested by the manufacturer for unexpected changes in a limited set of components such as toxins, nutrients, or allergens that are present in the unmodified food. The manufacturer's data is then assessed by a regulatory agency, such as the U.S. Food and Drug Administration. That data, along with data on the genetic modification itself and resulting proteins (or lack of protein), is submitted to regulators. If regulators determine that the submitted data show no significant difference between the modified and unmodified products, then the regulators will generally not require further food safety testing. However, if the product has no natural equivalent, or shows significant differences from the unmodified food, or for other reasons that regulators may have (for instance, if a gene produces a protein that had not been a food component before), the regulators may require that further safety testing be carried out.[37]

A 2003 review in Trends in Biotechnology identified seven main parts of a standard safety test:[86]

There has been discussion about applying new biochemical concepts and methods in evaluating substantial equivalence, such as metabolic profiling and protein profiling. These concepts refer, respectively, to the complete measured biochemical spectrum (total fingerprint) of compounds (metabolites) or of proteins present in a food or crop. The goal would be to compare overall the biochemical profile of a new food to an existing food to see if the new food's profile falls within the range of natural variation already exhibited by the profile of existing foods or crops. However, these techniques are not considered sufficiently evaluated, and standards have not yet been developed, to apply them.[87]

Transgenic animals have genetically modified DNA. Animals are different from plants in a variety of waysbiology, life cycles, or potential environmental impacts.[88] GM plants and animals were being developed around the same time, but due to the complexity of their biology and inefficiency with laboratory equipment use, their appearance in the market was delayed.[89]

There are six categories that genetically engineered (GE) animals are approved for:[90]

The literature about Biodiversity and the GE food/feed consumption has sometimes resulted in animated debate regarding the suitability of the experimental designs, the choice of the statistical methods or the public accessibility of data. Such debate, even if positive and part of the natural process of review by the scientific community, has frequently been distorted by the media and often used politically and inappropriately in anti-GE crops campaigns.

Domingo, Jos L.; Bordonaba, Jordi Gin (2011). "A literature review on the safety assessment of genetically modified plants" (PDF). Environment International. 37 (4): 734742. doi:10.1016/j.envint.2011.01.003. PMID21296423. In spite of this, the number of studies specifically focused on safety assessment of GM plants is still limited. However, it is important to remark that for the first time, a certain equilibrium in the number of research groups suggesting, on the basis of their studies, that a number of varieties of GM products (mainly maize and soybeans) are as safe and nutritious as the respective conventional non-GM plant, and those raising still serious concerns, was observed. Moreover, it is worth mentioning that most of the studies demonstrating that GM foods are as nutritional and safe as those obtained by conventional breeding, have been performed by biotechnology companies or associates, which are also responsible of commercializing these GM plants. Anyhow, this represents a notable advance in comparison with the lack of studies published in recent years in scientific journals by those companies.

Krimsky, Sheldon (2015). "An Illusory Consensus behind GMO Health Assessment" (PDF). Science, Technology, & Human Values. 40 (6): 132. doi:10.1177/0162243915598381. I began this article with the testimonials from respected scientists that there is literally no scientific controversy over the health effects of GMOs. My investigation into the scientific literature tells another story.

And contrast:

Panchin, Alexander Y.; Tuzhikov, Alexander I. (January 14, 2016). "Published GMO studies find no evidence of harm when corrected for multiple comparisons". Critical Reviews in Biotechnology. 37 (2): 15. doi:10.3109/07388551.2015.1130684. ISSN0738-8551. PMID26767435. Here, we show that a number of articles some of which have strongly and negatively influenced the public opinion on GM crops and even provoked political actions, such as GMO embargo, share common flaws in the statistical evaluation of the data. Having accounted for these flaws, we conclude that the data presented in these articles does not provide any substantial evidence of GMO harm.

The presented articles suggesting possible harm of GMOs received high public attention. However, despite their claims, they actually weaken the evidence for the harm and lack of substantial equivalency of studied GMOs. We emphasize that with over 1783 published articles on GMOs over the last 10 years it is expected that some of them should have reported undesired differences between GMOs and conventional crops even if no such differences exist in reality.

and

Yang, Y.T.; Chen, B. (2016). "Governing GMOs in the USA: science, law and public health". Journal of the Science of Food and Agriculture. 96 (6): 185155. doi:10.1002/jsfa.7523. PMID26536836. It is therefore not surprising that efforts to require labeling and to ban GMOs have been a growing political issue in the USA (citing Domingo and Bordonaba, 2011).

Overall, a broad scientific consensus holds that currently marketed GM food poses no greater risk than conventional food... Major national and international science and medical associations have stated that no adverse human health effects related to GMO food have been reported or substantiated in peer-reviewed literature to date.

Despite various concerns, today, the American Association for the Advancement of Science, the World Health Organization, and many independent international science organizations agree that GMOs are just as safe as other foods. Compared with conventional breeding techniques, genetic engineering is far more precise and, in most cases, less likely to create an unexpected outcome.

Pinholster, Ginger (October 25, 2012). "AAAS Board of Directors: Legally Mandating GM Food Labels Could "Mislead and Falsely Alarm Consumers"". American Association for the Advancement of Science. Retrieved February 8, 2016.

"REPORT 2 OF THE COUNCIL ON SCIENCE AND PUBLIC HEALTH (A-12): Labeling of Bioengineered Foods" (PDF). American Medical Association. 2012. Archived from the original (PDF) on 7 September 2012. Retrieved March 21, 2017. Bioengineered foods have been consumed for close to 20 years, and during that time, no overt consequences on human health have been reported and/or substantiated in the peer-reviewed literature.

GM foods currently available on the international market have passed safety assessments and are not likely to present risks for human health. In addition, no effects on human health have been shown as a result of the consumption of such foods by the general population in the countries where they have been approved. Continuous application of safety assessments based on the Codex Alimentarius principles and, where appropriate, adequate post market monitoring, should form the basis for ensuring the safety of GM foods.

"Genetically modified foods and health: a second interim statement" (PDF). British Medical Association. March 2004. Retrieved March 21, 2016. In our view, the potential for GM foods to cause harmful health effects is very small and many of the concerns expressed apply with equal vigour to conventionally derived foods. However, safety concerns cannot, as yet, be dismissed completely on the basis of information currently available.

When seeking to optimise the balance between benefits and risks, it is prudent to err on the side of caution and, above all, learn from accumulating knowledge and experience. Any new technology such as genetic modification must be examined for possible benefits and risks to human health and the environment. As with all novel foods, safety assessments in relation to GM foods must be made on a case-by-case basis.

Members of the GM jury project were briefed on various aspects of genetic modification by a diverse group of acknowledged experts in the relevant subjects. The GM jury reached the conclusion that the sale of GM foods currently available should be halted and the moratorium on commercial growth of GM crops should be continued. These conclusions were based on the precautionary principle and lack of evidence of any benefit. The Jury expressed concern over the impact of GM crops on farming, the environment, food safety and other potential health effects.

The Royal Society review (2002) concluded that the risks to human health associated with the use of specific viral DNA sequences in GM plants are negligible, and while calling for caution in the introduction of potential allergens into food crops, stressed the absence of evidence that commercially available GM foods cause clinical allergic manifestations. The BMA shares the view that that there is no robust evidence to prove that GM foods are unsafe but we endorse the call for further research and surveillance to provide convincing evidence of safety and benefit.

Originally posted here:
Regulation of genetic engineering - Wikipedia

Read More...

Master of Science in Genetic Counseling | Medical and …

October 2nd, 2019 2:45 am

The Genetic Counseling Graduate Program at IU School of Medicine is a 21-month Masters level program thats accredited by the Accreditation Council for Genetic Counseling (ACGC). The program offers comprehensive training and hands-on clinical experience to prepare students for a challenging and rewarding career in genetic counseling. The programs faculty and staff are proud to have contributed to the training of accomplished genetic counselors for more than 25 years.

Students learn through a variety of courses on genetics, laboratory and psychosocial topics as well as through extensive clinical experience and individual clinical research. Graduates of this MS program are accomplished in all areas of genetic counseling, including cancer, prenatal and pediatric genetics, public health genomics and industry, and they have a strong record of success on the ABGC board examination.

The Genetic Counseling Graduate Program curriculumbegins with a fall semester of didactic courses and clinical observations that focus on the basics of human genetics and enable students to begin practical application of skills in clinical case research and preparation, medical documentation, and patient counseling in the clinical setting. Clinical rotations begin in the spring semester of the first year and continue throughout the summer semester and entire second academic year. Successful completion of the Genetic Counseling graduate program at IU School of Medicine leads to a Master of Science degree in medical genetics.

Students in this program are supervised by supportive, experienced, licensed certified genetic counselors and board-certified medical geneticists. The curriculum offers deep clinical experience, which requires active participation in all aspects of the case preparation, counseling and follow-up as well as experience across numerous specialty areas, including pediatrics, cancer, prenatal diagnostics, metabolism, cardiovascular genetics, neurogenetics, and more.

More here:
Master of Science in Genetic Counseling | Medical and ...

Read More...

What is genetic testing? – Genetics Home Reference – NIH

October 2nd, 2019 2:45 am

Genetic testing is a type of medical test that identifies changes in chromosomes, genes, or proteins. The results of a genetic test can confirm or rule out a suspected genetic condition or help determine a persons chance of developing or passing on a genetic disorder. More than 1,000 genetic tests are currently in use, and more are being developed.

Several methods can be used for genetic testing:

Chromosomal genetic tests analyze whole chromosomes or long lengths of DNA to see if there are large genetic changes, such as an extra copy of a chromosome, that cause a genetic condition.

Genetic testing is voluntary. Because testing has benefits as well as limitations and risks, the decision about whether to be tested is a personal and complex one. A geneticist or genetic counselor can help by providing information about the pros and cons of the test and discussing the social and emotional aspects of testing.

Originally posted here:
What is genetic testing? - Genetics Home Reference - NIH

Read More...

Embryo – Wikipedia

October 2nd, 2019 2:44 am

An embryo is an early stage of development of a multicellular diploid eukaryotic organism. In general, in organisms that reproduce sexually, an embryo develops from a zygote, the single cell resulting from the fertilization of the female egg cell by the male sperm cell. The zygote possesses half the DNA from each of its two parents. In plants, animals, and some protists, the zygote will begin to divide by mitosis to produce a multicellular organism. The result of this process is an embryo.

In human pregnancy, a developing fetus is considered as an embryo until the ninth week, fertilization age, or eleventh-week gestational age. After this time the embryo is referred to as a fetus.[1]

First attested in English in the mid-14c., the word embryon derives from Medieval Latin embryo, itself from Greek (embruon), lit. "young one",[2] which is the neuter of (embruos), lit. "growing in",[3] from (en), "in"[4] and (bru), "swell, be full";[5] the proper Latinized form of the Greek term would be embryum.

In animals, the development of the zygote into an embryo proceeds through specific recognizable stages of blastula, gastrula, and organogenesis. The blastula stage typically features a fluid-filled cavity, the blastocoel, surrounded by a sphere or sheet of cells, also called blastomeres. In a placental mammal, an ovum is fertilized in a fallopian tube through which it travels into the uterus. An embryo is called a fetus at a more advanced stage of development and up until birth or hatching. In humans, this is from the eleventh week of gestation. However, animals which develop in eggs outside the mother's body, are usually referred to as embryos throughout development; e.g. one would refer to a chick embryo, not a "chick fetus", even at later stages.

During gastrulation the cells of the blastula undergo coordinated processes of cell division, invasion, and/or migration to form two (diploblastic) or three (triploblastic) tissue layers. In triploblastic organisms, the three germ layers are called endoderm, ectoderm, and mesoderm. The position and arrangement of the germ layers are highly species-specific, however, depending on the type of embryo produced. In vertebrates, a special population of embryonic cells called the neural crest has been proposed as a "fourth germ layer", and is thought to have been an important novelty in the evolution of head structures.

During organogenesis, molecular and cellular interactions between germ layers, combined with the cells' developmental potential, or competence to respond, prompt the further differentiation of organ-specific cell types.[citation needed] For example, in neurogenesis, a subpopulation of ectoderm cells is set aside to become the brain, spinal cord, and peripheral nerves. Modern developmental biology is extensively probing the molecular basis for every type of organogenesis, including angiogenesis (formation of new blood vessels from pre-existing ones), chondrogenesis (cartilage), myogenesis (muscle), osteogenesis (bone), and many others.

In botany, a seed plant embryo is part of a seed, consisting of precursor tissues for the leaves, stem (see hypocotyl), and root (see radicle), as well as one or more cotyledons. Once the embryo begins to germinategrow out from the seedit is called a seedling (plantlet).

Bryophytes and ferns also produce an embryo, but do not produce seeds. In these plants, the embryo begins its existence attached to the inside of the archegonium on a parental gametophyte from which the egg cell was generated. The inner wall of the archegonium lies in close contact with the "foot" of the developing embryo; this "foot" consists of a bulbous mass of cells at the base of the embryo which may receive nutrition from its parent gametophyte. The structure and development of the rest of the embryo varies by group of plants. As the embryo has expanded beyond the enclosing archegonium, it is no longer termed an embryo.

Embryos are used in various fields of research and in techniques of assisted reproductive technology. An egg may be fertilized in vitro and the resulting embryo may be frozen for later use.The potential of embryonic stem cell research, reproductive cloning, and germline engineering are currently being explored. Prenatal diagnosis or preimplantation diagnosis enables testing embryos for diseases or conditions.

Cryoconservation of animal genetic resources is a practice in which animal germplasms, such as embryos are collected and stored at low temperatures with the intent of conserving the genetic material.

The embryos of Arabidopsis thaliana have been used as a model to understand gene activation, patterning, and organogenesis of seed plants.[6]

In regards to research using human embryos, the ethics and legalities of this application continue to be debated.[7][8][9]

Researchers from MERLN Institute and the Hubrecht Institute in the Netherlands managed to grow samples of synthetic rodent embryoids, combining certain types of stem cells. This method may assist scientists to understand the very first moments of the process of the birth of a new life, which, in turn, can lead to the emergence of new effective methods to combat infertility and other genetic diseases.[10]

Fossilized animal embryos are known from the Precambrian, and are found in great numbers during the Cambrian period. Even fossilized dinosaur embryos have been discovered.[11]

Some embryos do not survive to the next stage of development. When this happens naturally, it is called spontaneous abortion or miscarriage.[12] There are many reasons why this may occur. The most common natural cause of miscarriage is chromosomal abnormality in animals[13] or genetic load in plants.[14]

In species which produce multiple embryos at the same time, miscarriage or abortion of some embryos can provide the remaining embryos with a greater share of maternal resources. This can also disturb the pregnancy, causing harm to the second embryo. Genetic strains which miscarry their embryos are the source of commercial seedless fruits.

Abortion is the process of artificially (non-naturally) removing the embryo through deliberate pharmaceutical or surgical methods.

Read more:
Embryo - Wikipedia

Read More...

What were some of the ethical, legal, and social …

October 2nd, 2019 2:44 am

The Ethical, Legal, and Social Implications (ELSI) program was founded in 1990 as an integral part of the Human Genome Project. The mission of the ELSI program was to identify and address issues raised by genomic research that would affect individuals, families, and society. A percentage of the Human Genome Project budget at the National Institutes of Health and the U.S. Department of Energy was devoted to ELSI research.

The ELSI program focused on the possible consequences of genomic research in four main areas:

Privacy and fairness in the use of genetic information, including the potential for genetic discrimination in employment and insurance.

The integration of new genetic technologies, such as genetic testing, into the practice of clinical medicine.

Ethical issues surrounding the design and conduct of genetic research with people, including the process of informed consent.

The education of healthcare professionals, policy makers, students, and the public about genetics and the complex issues that result from genomic research.

Follow this link:
What were some of the ethical, legal, and social ...

Read More...

Are moles determined by genetics? – Genetics Home …

October 2nd, 2019 2:44 am

Moles are very common, especially in people with fair skin. Moles are overgrowths of skin cells called melanocytes, but the genetic factors involved in their development are not well understood. Although moles, like tumors, are an overgrowth of cells, moles are almost always noncancerous (benign). Perhaps because most moles are benign, scientists have not studied them extensively, and not much is known about their genetics. Similar numbers of moles seem to occur on individuals of different generations of a family, so a tendency to develop moles seems to be inherited, but the inheritance pattern is not well understood.

Most moles occur on parts of the body that are exposed to the sun (ultraviolet radiation), and the number of moles an individual has may increase after extended time in the sun. Moles usually begin to occur in childhood. These moles are called acquired melanocytic nevi (and include the subtype epidermal nevus). It is common for new moles to appear during times when hormone levels change, such as adolescence and pregnancy. During an individuals lifetime, moles may change in appearance; hair may grow out of them, and they can change in size and shape, darken, fade, or disappear. Infants and the elderly tend to have the fewest moles.

Sometimes, moles are present at birth or develop during infancy. These moles, which are called congenital nevi, are almost always benign. Rarely, a very large mole, called a giant congenital melanocytic nevus, is present at birth. In rare cases, the most serious type of skin cancer (called melanoma) may develop in this type of mole.

Large, irregularly shaped and colored moles called dysplastic nevi or atypical moles can occur at any age. Although not common, they tend to be numerous, and they increase a persons risk of melanoma. Heredity contributes to the development of dysplastic nevi and to having a higher-than-average number of benign moles. Spending a lot of time in the sun can also increase the number of moles a person has. However, moles are often found on areas of the body that are not exposed, which suggests that factors other than ultraviolet radiation from the sun, perhaps hormones or other biologic processes, are involved in triggering the development of acquired melanocytic nevi and dysplastic nevi.

Although the genetics of melanoma has been widely studied, much less is known about genes involved in the development of benign moles. Variations in several genes, including FGFR3, PIK3CA, HRAS, and BRAF, are involved with benign moles. The most-studied of these is the BRAF gene. A mutation in BRAF leads to the production of an altered protein that causes melanocytes to aggregate into moles. This altered protein also triggers the production of a tumor-suppressor protein called p15 that stops moles from growing too big. In rare cases, BRAF mutations together with deletion of the CDKN2A gene causes a lack of p15, which creates the potential for mole cells to grow uncontrollably and become cancerous (malignant). The formation of cancer is increasingly likely when combined with environmental factors, such as cell damage caused by ultraviolet radiation exposure.

In susceptible individuals (those with fair skin, light hair, skin that burns instead of tans, a family history of melanoma, and genetic risk factors such as deletion of or mutations in the CDKN2A gene), ultraviolet radiation from repeated sun exposure can damage existing moles, increasing their risk of becoming malignant. Research has shown that individuals who have an abundance of moles are at an increased risk of melanoma. However, some people who are diagnosed with melanoma have few moles, and melanoma often develops in areas of the body that are not exposed to the sun. Researchers are working to identify additional susceptibility genes to better understand the genetics of moles and their relationship with cancer.

Plasmeijer EI, Nguyen TM, Olsen CM, Janda M, Soyer HP, Green AC. The natural history of common melanocytic nevi: a systematic review of longitudinal studies in the general population. J Invest Dermatol. 2017 Sep;137(9):2017-2018. doi: 10.1016/j.jid.2017.03.040. Epub 2017 May 18. PubMed: 28528913.

Roh MR, Eliades P, Gupta S, Tsao H. Genetics of melanocytic nevi. Pigment Cell Melanoma Res. 2015 Nov;28(6):661-72. doi: 10.1111/pcmr.12412. PubMed: 26300491. Free full-text available from PubMed Central: PMC4609613.

Silva JH1, S BC, Avila AL, Landman G, Duprat Neto JP. Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma - review article. Clinics (Sao Paulo). 2011;66(3):493-9. PubMed: 21552679. Free full-text available from PubMed Central: PMC3072014.

Here is the original post:
Are moles determined by genetics? - Genetics Home ...

Read More...

How to Boost Your Immune System – draxe.com

October 2nd, 2019 2:44 am

We are continually exposed to organisms that are inhaled, swallowed or inhabit our skin and mucous membranes. Whether or not these organisms lead to disease is decided by the integrity of our bodys defense mechanisms, or immune system. When our immune system is working properly, we dont even notice it. But when we have an under- or over-active immune system, we are at a greater risk of developing infections and other health conditions.

If you are wondering how to boost your immune system, look no further these 10 antimicrobial, immune-stimulating and antiviral supplements and essential oils can be used at home to improve your health.

The immune system is an interactive network oforgans, cells and proteins that protect the body from viruses and bacteria or any foreign substances. The immune system works to neutralize and remove pathogens like bacteria, viruses, parasites or fungi that enter the body, recognize and neutralize harmful substances from the environment, and fight against the bodys own cells that have changes due to an illness. (1)

The cells of the immune system originate in the bone marrow, then migrate to guard the peripheral tissues, circulating in the blood and in the specialized system of vessels called the lymphatic system.

When our immune system is working properly, we dont even notice it. Its when the performance of our immune system is compromised that we face illness. Underactivity of the immune system results in severe infections and tumors of immunodeficiency, while overactivity results in allergic and autoimmune diseases. (2)

For our bodys natural defenses to run smoothly, the immune system must be able to differentiate between self and non-self cells, organisms and substances. Non-self substances are called antigens, which includes the proteins on the surfaces of bacteria, fungi and viruses. When the cells of the immune system detect the presence of an antigen, the immune system recalls stored memories in order to quickly defend itself against known pathogens.

However, our own cells also have surface proteins, and its important that the immune system does not work against them. Normally, the immune system has already learned at an earlier stage to identify these cells proteins as self, but when it identifies its own body as non-self, this is called an autoimmune reaction. (3)

The amazing thing about the immune system is that its constantly adapting and learning so that the body can fight against bacteria or viruses that change over time. There are two parts of the immune system our innate immune system works as a general defense against pathogens and our adaptive immune system targets very specific pathogens that the body has already has contact with. These two immune systemscomplement each other in any reaction to a pathogen or harmful substance. (4)

Before learning exactly how to boost your immune system, first understand that most immune disorders result from either an excessive immune response or an autoimmune attack. Disorders of the immune system include:

Allergiesare a immune-mediated inflammatory response to normally harmless environmental substances known as allergens, which results in one or more allergic diseases such as asthma, allergic rhinitis, atopic dermatitis and food allergies. When the body overreacts to an allergen, such as dust, mold or pollen, it causes an immune reaction that leads to the development of allergy symptoms.

Allergies and asthma is a growing epidemic, affecting people of all ages, races, genders and socioeconomic statuses. In the U.S., it is estimated that more than 35 million people, mostly children, suffer from asthma symptoms. (5)An immune response to an allergic can be mild, from coughing and a runny nose, to a life-threatening reaction known as anaphylaxis. A person becomes allergic to a substance when the body develops antigens against it and has a reaction upon repeated exposure to that substance.

An immune deficiency disease is when the immune system is missing one or more of its parts, and it reacts too slowly to a threat. Immune deficiency diseases can be caused by medications or illness, or it may be a genetic disorder, which is called primary immunodeficiency. (6)

Some immune deficiency diseases include severe combined immune deficiency, common variable immune deficiency, human immunodeficiency virus/acquired immune deficient syndrome (HIV/AIDS), drug-induced immune deficiency and graft versus host syndrome. All of these conditions are due to a severe impairment of the immune system, which leads to infections that are sometimes life-threatening.

Autoimmune diseases cause your immune system to attack your own bodys cells and tissues in response to an unknown trigger. Autoimmune diseases have registered an alarming increase worldwide since the end of the Second World War, with more than 80 autoimmune disorders and increases in both the incidence and prevalence of these conditions. (7)

Fiftymillion Americans are living with an autoimmune disease today, and for many of them, its hard to get an accurate diagnosis right away. In fact, it often takes about five years to receive a diagnosis because autoimmune disease symptoms are so disparate and vague. Examples of autoimmune diseases include rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, type 1 diabetes, psoriasis, Graves disease (overactive thyroid), Hashimotos disease (underactive thyroid) and vasculitis.

Treatment for autoimmune diseases typically focus on reducing the immune systems activity, but your first line of defense should be addressing leaky gut and removing foods and factors that damage the gut. Several studies have shown that increased intestinal permeability is associated with several autoimmune diseases, and it appears to be involved in disease pathogenesis. (8)

When searching for how to boost your immune system, look to these 10 herbs, supplements and essential oils.

Many of echinaceas chemical constituents are powerful immune system stimulants that can provide significant therapeutic value. Research shows that one of the most significant echinacea benefits is its effects when used on recurring infections. A 2012 study published in Evidence-Based Complementary and Alternative Medicine found that echinacea showed maximal effects on recurrent infections, and preventive effects increased when participants used echinacea to prevent the common cold. (9)

A 2003 study conducted at the University of Wisconsin Medical School found that echinacea demonstrates significant immunomodulatory activities. After reviewing several dozen human experiments, including a number of blind randomized trials, researchers indicate that echinacea has several benefits, including immunostimulation, especially in the treatment of acute upper respiratory infection. (10)

The berries and flowers of the elder plant have been used as medicine for thousands of years. Even Hippocrates, the father of medicine, understood that this plant was key for how to boost your immune system. He used elderberry because of its wide array of health benefits, including its ability to fight colds, the flu, allergies and inflammation. Several studies indicate that elderberry has the power to boost the immune system, especially because it has proven to help treat the symptoms of the common cold and flu.

A study published in the Journal of International Medical Research found that when elderberry was used within the first 48 hours of onset of symptoms, the extract reduced the duration of the flu, with symptoms being relieved on an average of four days earlier. Plus, the use of rescue medication was significantly less in those receiving elderberry extract compared with placebo. (11)

Dating back to ancient times, silver was a popular remedy to stop the spread of diseases. Silver has historically and extensively been used as a broad-spectrum antimicrobial agent. Research published in the Journal of Alternative and Complementary Medicine suggests that colloidal silver wasable to significantly inhibit the growth the bacteria grown under aerobic and anaerobic conditions. (12)

To experience colloidal silver benefits, it can be used in several ways. How toboost your immune system with this supplement? Simply take one drop of true colloidal silver with internally. It can also be applied to the skin to help heal wounds, sores and infections. Always keep in mind that it should not be used for more than 14 days in a row.

You may come across many warnings about colloidal silver causing an irreversible condition called argyria (when people turn blue); however, this is caused by the misuse of products that are not true colloidal silver, like ionic or silver protein. (13)

Because leaky gut is a major cause of food sensitivities, autoimmune disease and immune imbalance or a weakened immune system, its important to consume probiotic foods and supplements. Probiotics are good bacteria that help you digest nutrients that boost the detoxification of your colon and support your immune system.

Research published in Critical Reviews in Food Science and Nutrition suggests that probiotic organisms may induce different cytokine responses. Supplementation of probiotics in infancy could help prevent immune-mediated diseases in childhood by improving the gut mucosal immune system and increasing the number of immunoglobulin cells and cytokine-producing cells in the intestines. (14)

Astragalusis a plant within the bean and legumes family that has a very long history as an immune system booster and disease fighter. Its root has been used as an adaptogen inTraditional Chinese Medicine for thousands of years. Although astragalus is one of the least studied immune-boosting herbs, there are some preclinical trials that show intriguing immune activity. (15)

A recent review published in the American Journal of Chinese Medicine found that astragalus-based treatments have demonstrated significant improvementof the toxicity induced by drugs such as immunosuppressants and cancer chemotherapeutics. Researchers concluded that astragalus extract has a beneficial effect on the immune system, and it protects the body from gastrointestinal inflammation and cancers. (16)

Ayurvedic medicine has relied ongingers ability for how toboost yourimmune system before recorded history. Its believed that ginger helps to break down the accumulation of toxins in our organs due to its warming effects. Its also known to cleanse the lymphatic system, our network of tissues and organs that help rid the body of toxins, waste and other unwanted materials.

Ginger root and ginger essential oil can treat a wide range of diseases with its immunonutrition and anti-inflammatory responses. Research shows that ginger has antimicrobial potential, which helps in treating infectious diseases. Its also known for its ability to treat inflammatory disorders that are caused by infectious agents such as viruses, bacteria and parasites, as well as physical and chemical agents like heat, acid and cigarette smoke. (17)

7. Ginseng

The ginseng plant, belonging to the Panax genus, can help you to boost your immune system and fight infections. The roots, stems and leaves of ginseng have been used for maintaining immune homeostasis and enhancing resistance to illness or infection. Ginseng improves the performance of your immune system by regulating each type of immune cell, including macrophages, natural killer cells, dendritic cells, T cells and B cells. It also has antimicrobial compounds that work as a defense mechanism against bacterial and viral infections. (18)

A study published in the American Journal of Chinese Medicine found that ginseng extract successfully induced antigenspecific antibody responses when it was administered orally. Antibodies bind to antigens, such as toxins or viruses, and keep them from contacting and harming normal cells of the body. Because of ginsengs ability to play a role in antibody production, it helps the body to fight invading microorganisms or pathogenic antigens. (19)

Vitamin D can modulate the innate and adaptive immune responses and a vitamin D deficiency is associated with increased autoimmunity as well as an increased susceptibility to infection. Research shows that vitamin D works to maintain tolerance and promote protective immunity. There have been multiple cross-sectional studies that associate lower levels of vitamin D with increased infection. (20)

One study conducted at Massachusetts General Hospital included 19,000 participants, and it showed that individuals with lower vitamin D levels were more likely to report a recent upper respiratory tract infection than those with sufficient levels, even after adjusting for variables such as season, age, gender, body mass and race. (21) Sometimes addressing a nutritional deficiency is how to boost your immune system.

Myrrh is a resin, or sap-like substance, that is one of the most widely used essential oils in the world. Historically, myrrh was used to treat hay fever, clean and heal wounds and stop bleeding. Myrrh strengthens the immune system with its antiseptic, antibacterial and antifungal properties. (22)

A 2012 study validated myrrhs enhanced antimicrobial efficacy when used in combination with frankincense oil against a selection of pathogens. Researchers concluded that myrrh oil has anti-infective properties and can help to boost your immune system. (23)

Oregano essential oil is known for its healing and immune-boosting properties. It fights infections naturally due to its antifungal, antibacterial, antiviral and anti-parasite compounds. A 2016 study published in Critical Reviews in Food Science and Nutrition found that the main compounds in oregano that are responsible for its antimicrobial activity include carvacrol and thymol. (24)

Several scientific studies found that oregano oil exhibited antibacterial activity againsta number of bacterial isolates and species, includingB. laterosporus andS. saprophyticus. (25)

I should also stress the importance of incorporating physical activity into your daily and weekly regimen to strengthen your immune system. A 2018 human study published in Aging Cell revealed that high levels of physical activity and exercise improve the immunosenescence (gradual deterioration of the immune system) in older adults aged 55 through 79, compared to those in the same age group who were physically inactive. The study also highlights that physical activity doesnt protect against all of the immunosenescence that occurs. However, the decrease in a persons immune system function and activity can be influenced by decreased physical activity in addition to age. (26)

In the quest for how to boost your immune system, proceed with some caution. If you are using these immune-boosting herbs and essential oils, remember that the products are extremely potent and should not be taken for more than two weeks at a time. Giving yourself a break in between long doses is important.

Also, if you are pregnant, be cautious when using essential oils and reach out to your health care provider before doing so. Any time you are using natural remedies like plant supplements, its a good idea to do it under the care of your doctor or nutritionist.

From the sound of it, you might think leaky gut only affects the digestive system,but in reality it can affect more. Because Leaky Gut is so common, and such an enigma,Im offering a free webinar on all things leaky gut.Click here to learn more about the webinar.

Go here to see the original:
How to Boost Your Immune System - draxe.com

Read More...

Immune System (for Teens) – KidsHealth

October 2nd, 2019 2:44 am

Larger text sizeLarge text sizeRegular text size

Whether you're stomping through the showers in your bare feet after gym class or touching the bathroom doorknob, you're being exposed to germs. Fortunately for most of us, the immune system is constantly on call to do battle with bugs that could put us out of commission.

The immune (pronounced: ih-MYOON) system, which is made up of special cells, proteins, tissues, and organs, defends people against germs and microorganisms every day. In most cases, the immune system does a great job of keeping people healthy and preventing infections. But sometimes, problems with the immune system can lead to illness and infection.

The immune system is the body's defense against infectious organisms and other invaders. Through a series of steps called the immune response, the immune system attacks organisms and substances that invade our systems and cause disease. The immune system is made up of a network of cells, tissues, and organs that work together to protect the body.

The cells that are part of this defense system include white blood cells, also called leukocytes (pronounced: LOO-kuh-sytes). They come in two basic types (more on these below), which combine to seek out and destroy the organisms or substances that cause disease.

Leukocytes are produced and stored in many locations throughout the body, including the thymus, spleen, and bone marrow. For this reason, they are called the lymphoid (pronounced: LIM-foyd) organs. There are also clumps of lymphoid tissue throughout the body, primarily in the form of lymph nodes, that house the leukocytes.

The leukocytes circulate through the body between the organs and nodes by means of the lymphatic (pronounced: lim-FAT-ik) vessels. (You can think of the lymphatic vessels as a type of highway between the rest stops that are the lymphoid organs and lymph nodes.) Leukocytes can also circulate through the blood vessels. In this way, the immune system works in a coordinated manner to monitor the body for germs or substances that might cause problems.

There are two basic types of leukocytes:

A number of different cells are considered phagocytes. The most common type is the neutrophil (pronounced: NOO-truh-fil), which primarily fights bacteria. So when doctors are worried about a bacterial infection, sometimes they order a blood test to see if a patient has an increased number of neutrophils triggered by the infection. Other types of phagocytes have their own jobs to make sure that the body responds appropriately to a specific type of invader.

There are two kinds of lymphocytes: the B lymphocytes and the T lymphocytes. Lymphocytes start out in the bone marrow and either stay and mature there to become B cells or leave for the thymus gland, where they mature to become T cells.

B lymphocytes and T lymphocytes have separate jobs to do: B lymphocytes are like the body's military intelligence system, seeking out their targets and sending defenses to lock onto them. T cells are like the soldiers, destroying the invaders that the intelligence system has identified. Here's how it works.

A foreign substance that invades the body is called an antigen (pronounced: AN-tih-jun). When an antigen is detected, several types of cells work together to recognize and respond to it. These cells trigger the B lymphocytes to produce antibodies (pronounced: AN-tye-bah-deez). Antibodies are specialized proteins that lock onto specific antigens. Antibodies and antigens fit together like a key and a lock.

Once the B lymphocytes recognize specific antigens, they develop a memory for the antigen and will produce antibodies the next time the antigen enters a person's body. That's why if someone gets sick with a certain disease, like chickenpox, that person typically doesn't get sick from it again.

This is also why we use immunizations to prevent certain diseases. The immunization introduces the body to the antigen in a way that doesn't make a person sick, but it does allow the body to produce antibodies that will then protect that person from future attack by the germ or substance that produces that particular disease.

Although antibodies can recognize an antigen and lock onto it, they are not capable of destroying it without help. That is the job of the T cells. The T cells are part of the system that destroys antigens that have been tagged by antibodies or cells that have been infected or somehow changed. (There are actually T cells that are called "killer cells.") T cells are also involved in helping signal other cells (like phagocytes) to do their jobs.

Antibodies can also neutralize toxins (poisonous or damaging substances) produced by different organisms. Lastly, antibodies can activate a group of proteins called complement that are also part of the immune system. Complement assists in killing bacteria, viruses, or infected cells.

All of these specialized cells and parts of the immune system offer the body protection against disease. This protection is called immunity.

Humans have three types of immunity innate, adaptive, and passive:

Everyone is born with innate (or natural) immunity, a type of general protection that humans have. Many of the germs that affect other species don't harm us. For example, the viruses that cause leukemia in cats or distemper in dogs don't affect humans. Innate immunity works both ways because some viruses that make humans ill such as the virus that causes HIV/AIDS don't make cats or dogs sick either.

Innate immunity also includes the external barriers of the body, like the skin and mucous membranes (like those that line the nose, throat, and gastrointestinal tract), which are our first line of defense in preventing diseases from entering the body. If this outer defensive wall is broken (like if you get a cut), the skin attempts to heal the break quickly and special immune cells on the skin attack invading germs.

We also have a second kind of protection called adaptive (or active) immunity. This type of immunity develops throughout our lives. Adaptive immunity involves the lymphocytes (as in the process described above) and develops as children and adults are exposed to diseases or immunized against diseases through vaccination.

Passive immunity is "borrowed" from another source and it lasts for a short time. For example, antibodies in a mother's breast milk provide an infant with temporary immunity to diseases that the mother has been exposed to. This can help protect the infant against infection during the early years of childhood.

Everyone's immune system is different. Some people never seem to get infections, whereas others seem to be sick all the time. As people get older, they usually become immune to more germs as the immune system comes into contact with more and more of them. That's why adults and teens tend to get fewer colds than kids their bodies have learned to recognize and immediately attack many of the viruses that cause colds.

Disorders of the immune system can be broken down into four main categories:

Immunodeficiencies (pronounced: ih-myoon-o-dih-FIH-shun-seez) happen when a part of the immune system is not present or is not working properly.

Sometimes a person is born with an immunodeficiency these are called primary immunodeficiencies. (Although primary immunodeficiencies are conditions that a person is born with, symptoms of the disorder sometimes may not show up until later in life.)

Immunodeficiencies also can be acquired through infection or produced by drugs. These are sometimes called secondary immunodeficiencies.

Immunodeficiencies can affect B lymphocytes, T lymphocytes, or phagocytes.The most common immunodeficiency disorder is IgA deficiency, in which the body doesn't produce enough of the antibody IgA, an immunoglobulin found primarily in the saliva and other body fluids that help guard the entrances to the body. People with IgA deficiency tend to have allergies or get more colds and other respiratory infections, but the condition is usually not severe.

Acquired (or secondary) immunodeficiencies usually develop after a person has a disease, although they can also be the result of malnutrition, burns, or other medical problems. Certain medicines also can cause problems with the functioning of the immune system.

Acquired (secondary) immunodeficiencies include:

Newborns can get HIV infection from their mothers while in the uterus, during the birth process, or during breastfeeding. Teens and adults can get HIV infection by having unprotected sexual intercourse with an infected person or from sharing contaminated needles for drugs, steroids, or tattoos.

In addition, people with autoimmune disorders or who have had organ transplants may need to take immunosuppressant medications. These medicines can also reduce the immune system's ability to fight infections and can cause secondary immunodeficiency.

In autoimmune disorders, the immune system mistakenly attacks the body's healthy organs and tissues as though they were foreign invaders.

Some autoimmune diseases include:

Allergic disorders happen when the immune system overreacts when exposued to antigens in the environment. The substances that provoke such attacks are called allergens. The immune response can cause symptoms such as swelling, watery eyes, and sneezing, and even a life-threatening reaction called anaphylaxis. Taking medications called antihistamines can relieve most symptoms.

Allergic disorders include:

Cancer happens when cells grow out of control. This can also happen with the cells of the immune system. Leukemia, which involves abnormal overgrowth of leukocytes, is the most common childhood cancer. Lymphoma involves the lymphoid tissues and is also one of the more common childhood cancers. With current medications most cases of both types of cancer in kids and teens are curable.

Although immune system disorders usually can't be prevented, you can help your immune system stay stronger and fight illnesses by staying informed about your condition and working closely with the doctor.

And if you're lucky enough to be healthy, you can help your immune system keep you that way by washing your hands often to avoid infection, eating right, getting plenty of exercise,and getting regular medical checkups.

Read the original:
Immune System (for Teens) - KidsHealth

Read More...

Immune System: Innate and Adaptive Immunity Explained

October 2nd, 2019 2:44 am

The immune system (or immunity) can be divided into two types - innate and adaptive immunity. This video has an immune system animation. The innate immune system consists of defenses against infection that are activated instantly as a pathogen attacks. Adaptive immunity (or acquired immunity) is a subsystem of the immune system that contains highly specialised systemic cells and processes that kill pathogens and prevent their growth in the body. Innate vs adaptive immunity: its important to realize that innate and adaptive immunity are different. Their differences are explained in the video in layman terms.

Our immune system is a fascinating entity, that functions in quite a unique and efficient manner. Comprising of various types of cells, it is prepared for any kind of breach in the fortress of our body, and is equipped to fight off a staggering number of intruders.In this video, we give you a brief overview of the immune system, and the basic types of cells involved, along with the function they carry out.

Each cell if the immune system carries out various roles, depending on the kind of threat the body is facing. However, they have certain basic roles which have been explained here.

References

https://ciiid.washington.edu/content/...http://www.biology.arizona.edu/immuno...http://sphweb.bumc.bu.edu/otlt/MPH-Mo...https://med.uth.edu/pathology/files/2...

SUBSCRIBE to get more such science videos! https://www.youtube.com/channel/UCcN3...

Follow us on Twitter! https://twitter.com/abc_science

Follow us on Facebook!https://facebook.com/sciabc

Follow our Website!https://www.scienceabc.com

Read more here:
Immune System: Innate and Adaptive Immunity Explained

Read More...

Benefits of Stem Cells

October 2nd, 2019 2:43 am

By: Ian Murnaghan BSc (hons), MSc - Updated: 25 Sep 2019| *Discuss

With all the controversy surrounding stem cells you may have missed hearing about many of the benefits for the health and medical fields. You may not even be aware that stem cells already have many applications for treating disease. Their potential to treat even more diseases in the future means that scientists are working hard to learn about how stem cells function and how they can treat some of the more serious diseases affecting the world.

The potential to reverse diseases is also not a foreign one.

Heart Attack - For example, a patient who has suffered from a heart attack and sustained heart damage could have the damaged tissue replaced by healthy new muscle cells.

Parkinson's Disease - The destruction of brain cells in conditions such as Parkinson's disease can hopefully be reversed with the replacement of new, healthy and functioning brain cells.

Genetic Defects - Even more promising is the potential to address genetic defects that are present from birth by restoring function and health with the introduction of normal healthy cells that do not have these defects.

Scientists aim to locate and remove specific stem cells from a tissue and then trigger them to differentiate outside of the body before transplanting them back into the patient to replace damaged tissues. In burn victims, a very small piece of the skin can be progressively grown, allowing doctors to cover a burn that is often much larger than the original size of the skin piece.

The current benefits of stem cell usage are already well documented and it is expected that continued research will pave the way for new treatments. For those suffering from serious diseases, stem cells offer hope for effective treatment or perhaps even a reversal of the disease. Time will confirm the full success of stem cell therapies and continued research should teach us more about using stem cells to treat debilitating medical conditions.

Check out the features on stem cell therapy on this site for more information.

You might also like...

Share Your Story, Join the Discussion or Seek Advice..

Lulu - 25-Sep-19 @ 9:15 PM

Ssutr - 4-Sep-19 @ 3:56 AM

Borlar - 25-Jul-19 @ 8:52 PM

Ayodele Paul - 7-Jul-19 @ 7:05 AM

Tummie - 29-Jun-19 @ 6:28 PM

Steve - 14-Jun-19 @ 9:03 PM

Marga - 13-Jun-19 @ 12:49 AM

Sayali - 31-May-19 @ 6:27 PM

Sayali - 31-May-19 @ 6:24 PM

Akash - 31-May-19 @ 6:21 PM

Mary willie - 31-May-19 @ 6:00 PM

my name jeff - 21-Mar-19 @ 4:39 PM

Bebery - 14-Mar-19 @ 6:52 PM

Vinny - 23-Oct-18 @ 4:26 PM

rajiv98 - 23-Oct-18 @ 2:33 PM

Lenora Williams - 23-Oct-18 @ 3:11 AM

Unknown - 14-Oct-18 @ 7:34 PM

jokfis - 27-Aug-18 @ 7:07 AM

Jokfis - 27-Aug-18 @ 7:01 AM

stacy - 24-Aug-18 @ 1:59 AM

Das - 20-Aug-18 @ 5:46 PM

Thoibi - 9-Jul-18 @ 12:22 PM

min - 4-Jul-18 @ 3:29 AM

Kdonzo22 - 23-Jun-18 @ 4:51 PM

Tina - 16-May-18 @ 8:30 PM

Chinki - 12-May-18 @ 5:34 AM

neeraj - 24-Mar-18 @ 1:40 PM

Manama - 22-Mar-18 @ 7:41 PM

krishna - 18-Mar-18 @ 2:01 PM

Rehan - 21-Feb-18 @ 6:43 AM

Title:

(never shown)

Read more:
Benefits of Stem Cells

Read More...

Pre-Med Summer Programs – TeenLife

October 2nd, 2019 2:43 am

I am a:

Parent/Guardian

Student (Age 13+)

Middle/High School Educator

Advisor/Other Professional

First Name

Last Name

Phone

Email

Address

City

State --------- Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming Outside U.S. Not Applicable District of Columbia Guam Puerto Rico Virgin Islands Multiple Locations

ZIP / Postal Code

Country --------- Argentina Aruba Australia Austria Bahamas Bali Barbados Belgium Belize Bolivia Bonaire Borneo Bosnia Botswana Brazil Bulgaria Burkina Faso Cambodia Cameroon Canada Chile China Colombia Costa Rica Croatia Cuba Czech Republic Denmark Dominican Republic Ecuador Egypt El Salvador Estonia Fiji Finland France Galapagos Islands Gambia Georgia Germany Ghana Greece Guadeloupe Guatemala Haiti Hawaii Honduras Hong Kong Hungary Iceland India Indonesia Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Korea Korea, Republic of Laos Latvia Lebanon Lithuania Madagascar Malawi Malaysia Mauritius Mexico Moldova, Republic of Mongolia Morocco Mozambique Multiple Locations Myanmar Namibia Nepal Netherlands New Zealand Nicaragua Nigeria Norway Oman Pakistan Panama Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Romania Russian Federation Rwanda Samoa Saudi Arabia Scotland Senegal Sikkim Singapore Slovakia Slovenia South Africa South Korea Spain Sri Lanka St. Vincent Swaziland Sweden Switzerland Taiwan Tajikistan Tanzania Thailand Timor-Leste Trinidad and Tobago Turkey Uganda Ukraine United Arab Emirates United Kingdom United States Unknown Uruguay Venezuela Vietnam Virgin Islands, Brit Wales Zambia Zimbabwe

High School Graduation Year (required)

Check this box if you are less than 13 years old.

If you checked the box above, enter your parent or guardian's email address here:

Child's Graduation Year (required)

School Type --------- Online Other Religious Private Public Semester Special Needs Vocational Year Abroad Home School Military Therapeutic and Emotional Growth Gifted

Organization

Questions or Comments

Yes, I would like to receive valuable information and resources from TeenLife.

By submitting this form I confirm that I am at least 13 years of age and give my consent to be contacted by by email as well as by phone and/or mail (if provided).

More here:
Pre-Med Summer Programs - TeenLife

Read More...

Dr Raj – Best Orthopedic Surgeon In Los Angeles & Beverly …

October 2nd, 2019 2:43 am

As one of the Best Orthopedic Surgeons in Beverly HIlls and Los Angeles CA, Dr. Raj provides the ultimate in state-of -the-art quality orthopedic care available and is always on the cutting edge of the latest surgical and nonsurgical technologies such as PRP (Platelet Rich Plasma) injections, stem cell injections for tendonitis and arthritis, minimally invasive surgery and more. As an orthopedic surgeon Beverly Hills trusts and respects, Dr. Raj believes that an important part of recovery starts before treatment, with educating the patient and their family members on all treatment options, both surgical and non-surgical.

Dr. Raj is a Double Board Certified best Orthopedic Surgeon in Los Angeles, who has been in private practice for 10 years. In his short career and at a young age, he has been named as one of Americas Top Orthopedists, been featured on the Best of LA and has received numerous other accolades and awards as one of the Top & Best Orthopedic doctors in Los Angeles & Beverly Hills. At our orthopedic clinic in Beverly Hills & Los Angeles, Dr. Rajs obsession for perfection and his outstanding team has led to unparalleled surgical results and an impeccable reputation which has garnered the attention of the media seeking his expert opinion, also resulting in numerous guest appearances on radio and television.

As a top Los Angeles orthopedic surgeon, Dr. Raj uses the most advanced techniques and technologies available, to reduce hospitalization and speed recovery. This includes cutting edge techniques for rotator cuff repair, ACL reconstruction, knee replacement, meniscal repair, fracture treatment and much more. The goal of the top Los Angeles orthopedic surgeon is to return you to full activity in the least amount of time possible!

Dr. Raj and his team of orthopedic surgeons in Beverly Hills & Los Angeles CA provides a VIP, concierge personalized service for out of state and international patients to help you recover quicker. In addition, we have catered to many international patients encompassing VIP accommodations.Dr. Raj provides top & best orthopedic surgery in Beverly Hills & Los Angeles CA. Contact Dr. Raj and get back to your life!

Read the original post:
Dr Raj - Best Orthopedic Surgeon In Los Angeles & Beverly ...

Read More...

Liver Cirrhosis Treatment with Stem Cells – Liver disease …

October 2nd, 2019 2:43 am

Liver cirrhosis treatment - Stem cells treatment clinic

Chronic liver disease is the fifth biggest killer in the world. When a serious damage occurs, the liver loses the ability to repair itself which becomes a life-threatening condition. The only treatment currently available is a liver transplant. Would regenerative medicine be able to help?

The liver is a multifunctional organ that plays a role in digestion, blood sugar control, blood clotting factors for healing, making amino acids, increasing red blood cell growth, fat and cholesterol transport and the removal of waste, especially toxic exposures and the metabolization of medications into their active ingredients.

Causes of Liver Disease:

Cirrhosis is a term that describes permanent scarring of the liver. Normal liver cells are replaced by scar tissue that cannot perform healthy liver function.

Acute liver failure may be life threatening and at one time it was deemed non reversible; however, stem cell regeneration has proven most effective.

The majority of the liver (80 %) is made up of liver cells called hepatocytes. These cells have an average lifespan of 150 days, which means that the liver is constantly renewing itself under normal conditions. It is the only organ in the body that can easily replace damaged cells, but if enough cells are lost, the liver may not be able to meet the needs of the body that leads to liver failure.

The liver is a regenerative organ, but it is limited in this ability depending on the energy reserve needed to heal and the host of responsibilities that must be attended to daily regardless of this central organs ability to keep up the pace.

Liver disease can progress to cirrhosis and liver failure. Associated complications include increased risk of bleeding and infection, malnutrition and weight loss, decreased cognitive function over time and an increased risk of cancer.

Reinforcing therapies can transfer us from a condition of day-to-day survival to ones in which we feel a better quality of life.

Treatment of liver options

Although the liver can be recovered, there are no warning signs it is failing until it is too late. Once the line is crossed between the chronic liver disease and the final stage or liver failure, there are fewer options. Up to now, there is no liver dialysis that can rehabilitate liver function in the way that kidney failure is treated. Transplantation is currently the only effective treatment for liver failure, but it has many drawbacks, including the risk of rejection, risks associated with surgery, and a shortage of donors. It is estimated that for every donor organ there are 30 patients on a waiting list, and many people die from end-stage liver disease waiting for a donor organ.

Although dozens of patients with acute liver failure have received hepatocyte transplants from cadaveric donors, with some improvement in liver function, the effects were short lived and there was no overall survival benefit. The major challenges with this approach shortage of cadaveric donors and immune suppression of patients are essentially the same as for whole organ transplants.

As far back as 2000, researchers showed that hepatocytes could grow in the body on non-liver cell sources. This phenomenon is called transdifferentiation. Today, we clinically use donated or autologous (from the patient) adipose tissue stem cells for treating liver disease. When introduced to the patients body, stem cells are transdifferentiating into hepatocytes as as well as producing soluble factors that promote regeneration and repair. There is also the possibility that the stem cells may be fusing with resident hepatocytes to direct their regeneration.

Mesenchymal stem cells are found throughout the adult body in tissues such as bone, muscle, cartilage and fat.

Mesenchymal stem cells are among the most multipotent stem cells that remain in our bodies after birth. This means that they are still able to make a variety of different cell types.

Many trials have shown that patients with liver cirrhosis have benefitted from autologous adipose tissue derived mesenchymal stem cells. We have proven results reversing the effects of hepatitis, cirrhosis and liver damage due to chemo and other drug therapies.

In Swiss Medica Clinic we deliver treatment with proven results supported by the assistance of highly qualified professionals who realize the importance of personalized care, quality and confidence and that leads to top standards of treatment.

Swiss Medica Clinic is an excellent centre that offers patients the most innovative therapies. In principle in our medical centres we use the unique technology of application of autologous photo activated stem cells previously extracted from fat cells using mini liposuction. The highest standards of treatment and investigative research are upheld at all times.

The package include:

Optional additional therapy:

Here is the original post:
Liver Cirrhosis Treatment with Stem Cells - Liver disease ...

Read More...

Gene Therapy – Hemophilia News Today

September 30th, 2019 9:45 pm

Gene therapy is an experimental treatment technique that uses genes or genetic material to treat or prevent disease. Human clinical trials are underway to test potential gene therapies forhemophilia.

Hemophilia is a genetic bloodclotting disorder where patients do not make enough of the factors that allow blood to clot. Without these factors, patients cannot stop bleeding when they are injured. Patients with more severe forms of the disease can experience spontaneous bleeding around the joints.

Gene therapy for hemophilia involves using a modified virus (which does not cause disease) to introduce a copy of the gene that encodes for the clotting factor thats missing in patients. Following treatment with the virus, patients should begin producing their own clotting factor normally.

CRISPR/Cas9 is another strategy that could allow a patients body to produce their own blood clotting factor. It uses a piece of genetic material and an enzyme that acts like molecular scissors to repair the genetic fault that causes clotting factor deficiency.

AMT-060is a gene therapy being developed byUniQureto treathemophilia B. Early results from an ongoing two-cohort Phase 1/2, non-randomized, open-label, multi-center clinical trial(NCT02396342) which included 10 patients with severe or moderately severe hemophilia B demonstrated a clinically significant and sustained increase in factor IX activity, a substantial reduction in factor IX replacement therapy usage, and a complete cessation of spontaneous bleeding episodes.

AMT-061 is uniQures second gene therapy candidate for patients with hemophilia B. It is developed to deliver a variant of the F9 gene that encodes for clotting factor IX called FIX-Padua. This variant carries the instructions to make factor IX protein that is eight times more active than the normal protein. A harmless virus vector is used to direct the delivery of FIX-Padua to the patients body. Interim results of an ongoing Phase 2B study (NCT03489291) testing the safety and efficacy of AMT-061 in three patients with severe to moderately severe hemophilia B showed increased factor IX activity, reduced risk of bleeding, and no adverse events. A multicenter Phase 3 study (NCT03569891) evaluating the safety, efficacy, and tolerability of AMT-061 in hemophilia B patients is also underway.

FLT180ais a gene therapy being developed byFreeline.A Phase 1 clinical trial (NCT03369444) is currently recruiting patients with hemophilia B in the U.K. to testFLT180a. A second Phase 2/3 study (NCT03641703) is also recruiting participants in the same location to investigate the long-term safety and durability of factor IX activity in participants who have been treated with FLT180a gene therapy.

Sangamo Therapeutics is developing a genome editing therapy for hemophilia B called SB-FIX. A Phase 1/2 clinical trial (NCT02695160) is currently recruiting participants at several sites in the U.S. and the U.K.

Fidanacogene elaparvovec (SPK-9001) is a treatment for hemophilia B being developed in a partnership between Spark Therapeutics and Pfizer. This therapy is currently being investigated in a Phase 2 clinical trial (NCT02484092).

SPK-8011 is a gene therapy for hemophilia A being developed by Spark Therapeutics.Preliminary results from Phase 1/2 clinical trials (NCT03003533) indicated that all five participants in the first two dose cohorts have shown persistent, stable clotting factor levels in their blood.

Spark Therapeutics is developing another gene therapy called SPK-8016, which is designed to help hemophilia A patients who have developed inhibitors against their own clotting factors. Patients are currently being recruited for a Phase 1/2 clinical trial (NCT03734588) in the U.S. to determine the effective dosage of the treatment.

Valoctocogene roxaparvovec (BMN 270) is a gene therapy being developed by Biomarinto treat hemophilia A. The therapy is currently in Phase 1/2 clinical trials (NCT02576795).

SB-525is a gene therapybeingdeveloped bySangamo Therapeuticsto treathemophilia A. A Phase 1/2 clinical trial(NCT03061201) is currently recruiting about 20 adults with hemophilia A at sites across the U.S. to evaluate the safety, tolerability, and efficacyof the treatment.

***

Hemophilia News Todayis strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment.This contentis not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Emily holds a Ph.D. in Biochemistry from the University of Iowa and is currently a postdoctoral scholar at the University of Wisconsin-Madison. She graduated with a Masters in Chemistry from the Georgia Institute of Technology and holds a Bachelors in Biology and Chemistry from the University of Central Arkansas.Emily is passionate about science communication, and, in her free time, writes and illustrates childrens stories.

Read the original here:
Gene Therapy - Hemophilia News Today

Read More...

Gene Therapy Archives | Genetic Literacy Project

September 30th, 2019 9:45 pm

Hundreds of clinical trials are underway studying the technologys potential use in a wide range of genetic disorders, cancer and HIV/AIDS. There is some debate over whether or not the US already has approved its first gene therapy treatment.

In August 2017, the Food and Drug Administration (FDA) approved a cancer therapya CAR-T treatment marketed as Kymriahthat uses a patients own T cells and is a variation of the gene therapy that is being developed to treat single-gene diseases. The T cells are extracted and genetically altered so that they have a new gene that codes for a protein, known as a chimeric antigen receptor (CAR), that is a hybrid of two immune system proteins. One part guides the cells to the cancer cell targets and the other alerts the immune system. The cells, programmed to target and kill leukemia cells, are then injected back into the patient. Another CAR-T treatment, marketed as Yescarta, was approved for adults with aggressive forms of non-Hodgkins lymphoma in October 2017.

Some in the scientific community have pushed back against the idea of calling Kymriah or Yescarta true gene therapies, since they dont actually repair or replace a deficient gene. Instead, they say the most likely candidate to gain the first US approval is Luxturna, a one-time treatment that targets a rare, inherited form of blindness. A key committee of independent experts voted unanimously in October 2017 to recommend approval by the FDA for the treatment developed by Spark Therapeutics. The FDA is not bound by the panels decision, though the agency traditionally acts on its recommendations.

Hundreds of research studies (clinical trials) are underway to test gene therapies as treatments for genetic conditions, cancer and HIV/AIDS. ClinicalTrials.gov, a service of the National Institutes of Health, provides easy access to information about clinical trials. There is also a list of gene therapy clinical trials that are accepting (or will accept) participants. Among the studies and research:

Read the original:
Gene Therapy Archives | Genetic Literacy Project

Read More...

Page 866«..1020..865866867868..880890..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick